Abstract
The management of patients with glioblastoma remains challenging with an average survival of 32–56 weeks. We report on a clinical trial of patients with recurrent glioblastoma treated with adenovirus/herpex simplex-thymidine kinase/ganciclovir (ADV/HSV-tk/GC).
Entry criteria for this study included: recurrent malignant glioma after surgical resection and conventional radiation therapy. At the time of recurrence, computerized volumetric resection of the tumor was performed and the ADV/HSV-tk complex was injected in the tumor bed. GC was administered 24 h after surgery (10 mg/kg/day) for 7 days. Patients were divided into 3 ADV/HSV-tk dose-escalating cohorts.
Adenoviral vector shedding, and local or systemic toxicity did not occur in this study. Magnetic resonance imaging showed lack of increased brain edema in the treated patients. Histological examination of the 5 patients that had repeated surgery after gene therapy treatment showed lack of tissue toxicity. Additionally, PCR for HSV-tk was negative in the brain 3 months after injection. The patients' Karnofsky score was maintained ≥70 in 8/10 patients (80%) and 5/9 patients (55%) 3 and 6 months respectively, after gene therapy. Ten of 11 patients survived ≥52 weeks from diagnosis with an average survival of 112.3 weeks. One patient is still alive 248 weeks from diagnosis.
These data show that the ADV/HSV-tk/GC complex at the dose used in this study is safe. Additional dose escalation is currently in progress.
Similar content being viewed by others
References
Salcman M: Glioblastoma multiforme. Am J Med Sci 279(2): 84-94, 1980
Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, Linet MS: Cancer surveillance series: brain and other central nervous sytems cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91: 1382-1390, 1999
Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z: A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomas. Neuro-Oncology 5: 1-10, 2003
Wrensch M, Minn Y, Chew T, Bondy M, Berger M: Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncology 4: 278-299, 2002
Albert FK, Forsting M et al.: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis [see comments]. Neurosurgery 34(1): 45-61, 1994
Choucair AK, Levin VA et al.: Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65: 654-658, 1986
Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a perspective cancer control strategy. Cancer Res 46: 5276-5281, 1986
Barba D, Hardin J et al.: Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg 79(5): 729-735, 1994
Boviatsis EJ, Chase M et al.: Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther 5(2): 183-191, 1994
Chen SH, Shine HD et al.: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91(8): 3054-3057, 1994
Colak A, Goodman JC et al.: Adenovirus-mediated gene therapy for experimental spinal cord tumors: tumoricidal efficacy and functional outcome. Brain Res 691(1-2): 76-82, 1995
Izquierdo M, Cortes M et al.: Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther 2(1): 66-69, 1995
Moolten FL, Wells JM: Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82(4): 297-300, 1990
Perez-Cruet MJ, Trask TW et al.: Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res 39(4): 506-511, 1994
Ram Z, Culver KW et al.: Toxicity studies of retroviralmediated gene transfer for the treatment of brain tumors. J Neurosurg 79(3): 400-407, 1993
Russell DW, Berger MS et al.: The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum Gene Ther 6(5): 635-641, 1995
Rainov NG, the GL1328 International Study Group: A phase III clinical evaluation of herpes simplex virus type I thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389-2401, 2000
Hoshino T, Wilson CB: Cell kinetic analyses of human malignant brain tumors (gliomas). Cancer 44(3): 956-962, 1979
Shine HD, Wyde PR et al.: Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat). Gene Ther 4(4): 275-279, 1997
Akli S, Caillaud C et al.: Transfer of a foreign gene into the brain using adenovirus vectors [see comments]. Nat Genet 3(3): 224-228, 1993
Bain D, Wilkinson GW et al.: Adenovirus vectors to transfer genes into neurones: implications for gene therapy of neurological disorders Gene Ther 1: S68, 1994
Le Gal La Salle G, Robert JJ et al.: An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259(5097): 988-990, 1993
Neve RL: Adenovirus vectors enter the brain. Trends Neurosci 16(7): 251-253, 1993
Shenk T, Flint J: Transcriptional and transforming activities of the adenovirus E1A proteins. Adv Cancer Res 57: 47-85, 1991
Viola JJ, Ram Z et al.: Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningeal cancer cells. J Neurosurg 82(1): 70-76, 1995
Graham FL, Prevec L: Methods for construction of adenovirus vectors. Mol Biotechnol 3(3): 207-220, 1995
Benveniste R, Germano IM: Evaluation of factors predicting accurate resection of high-grade gliomas using frameless image-guided stereotactic guidance. Neurosurgical Focus 14: 1-4, 2003
Germano IM, Villalobos H, Silvers A, Post K: Clinical use of the neurostation for intracranial computer-assisted neuronavigation. Neurosurgery 45: 261-270, 1999
Germano IM, Kondo S: Image-guided tumor resection. In: Germano IM (ed) Advanced Techniques in Image-Guided Neurosurgery. Thieme Publisher, NY, 2001, pp 1-10
Burhies WC, Mastre BJ, Tinker AJ, Strand V, Koretz SH, the Syntex Collaborative gancyclovir treatment Study Group: Ganciclovir treatment of sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 10: 495-506, 1988
Oldfield EH, Ram Z et al.: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4(1): 39-69, 1993
Horellou P, Vigne E et al.: Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. Neuroreport 6(1): 49-53, 1994
Chiocca AE: Oncolytic viruses. Nat Rev Cancer 2: 938-950, 2002
Smith: Hum Gene Ther 8: 943-954, 1997
Weber FW, Floeth FW, Reifenberger G, Felsberg J, Aulich A, Kiwit JCW, Bock WJ: MRI characteristics and histological changes in glioblastoma after gene therapy. Front Radiat Ther Oncol 33: 244-252, 1999
Klatzmann D, Valery CA et al.: A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9(17): 2595-2604, 1998
Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Soresen AG, Barbier N: A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme for tumor transduction with herpes simplex thymidine kinase gene followed by ganciclovir. Hum gene Ther 10: 2325-2335, 1999
Goodman JC, Trask TW et al.: Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies. Hum Gene Ther 7(10): 1241-1250, 1996
Packer RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, Landfond d, McComb JG, Cogen PH, Vezina G, Kapkala LP: Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpex simplex virus thymidine kinase gene vestor-producer cells followed by intravenous ganciclovir administration J Neurosurg 92, 249-254, 2000
Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M: The safety of interstitial chemotherapy with BCNUloaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neuro-Oncol 26: 111-123, 1995
Kramer ED, Packer RJ, Ginsberg J, Goldman S, Thompson S, Bayer LA, Shen V, Harris R, Khan S, Finlay JL: Acute neurologic dysfunction associated with high dose chemotherapy and autologous bone marrow rescue for primary malignant brain tumors. Pediatric Neurosurg 27: 230-237, 1997
Prados MD, Russo C: Chemotherapy of brain tumors.Semin Surg Oncol 14: 88-95, 1998
Deliganis AV, Baxter AB et al.: Serial MR in gene therapy for recurrent glioblastoma: initial experience and work in progress. AJNR 18(8): 1401-1406, 1997
Colombo F, Zanusso M et al.: Gene stereotactic neurosurgery for recurrent malignant gliomas. Stereotact Funct Neurosurg 68(1-4): 245-251, 1997
Palu G, Cavaggioni A, Calvi P, Franchin E, Pizzato M, Boschetto R, Parolin C, Chilosi M, Ferrini S, Zanusso A, Colombo F 6: 330-337, 1999
Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL: A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy, Neuroncology 4: 261-267, 2002
Osamura T, Mizuta R et al.: Isolation of adenovirus type 11 from the brain of a neonate with pneumonia and encephalitis. Eur J Pediatr 152(6): 496-499, 1993
Rainov NG, Kramm CM, Aboody Guterman K, Chase M, Ueki K, Louis DN, Harsh GR 4th, Chiocca A: Retrovirusmediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther 3: 99-106, 1996
Ram Z, Culver KW et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells [see comments]. Nat Med 3(12): 1354-1361, 1997
Rosenberg SA, Blaese RM et al.: Human gene Marker/therapy clinical protocols. Hum Gene Ther 7(13): 1621-1647, 1996
Takamiya Y, Short MP et al.: An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 79(1): 104-110, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Germano, I.M., Fable, J., Humayun Gultekin, S. et al. Adenovirus/Herpes Simplex-Thymidine Kinase/Ganciclovir Complex: Preliminary Results of a Phase I trial in Patients with Recurrent Malignant Gliomas. J Neurooncol 65, 279–289 (2003). https://doi.org/10.1023/B:NEON.0000003657.95085.56
Issue Date:
DOI: https://doi.org/10.1023/B:NEON.0000003657.95085.56